Lonika Lodha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lonika Lodha has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Reeta Subramaniam Mani
Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bengaluru, India
7 shared publications - Manoor Ananda Ashwini
Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS), Karnataka, India
5 shared publications - Amrita Pattanaik
Manipal Institute of Virology, Manipal Academy of Higher Education (MAHE), Manipal, India
2 shared publications Sathya Priya Manuel
Department of Neurovirology National Institute of Mental Health & Neurosciences (NIMHANS) Bangalore India
2 shared publications- Shipra Gupta
Department of Neurovirology National Institute of Mental Health and Neurosciences (NIMHANS) Bengaluru Karnataka India
2 shared publications Shubhangi Chandel
Department of Neurovirology, National Institute of Mental Health and Neurosciences (NIMHANS) , Bengaluru
2 shared publications
Latest Publications
- 7 November 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- p. 1
Melioidosis in a Sibling Following a Complex Index Case
- 7 November 2026
- Published by Springer Nature in Indian Journal of Pediatrics
- p. 1
Melioidosis in a Sibling Following a Complex Index Case
- 20 August 2026
- Published by Springer Nature in VirusDisease
- Vol. 37 (3) , 391-395
Evaluation of the quantiplus rabies virus detection kit for diagnosis of rabies in humans and animals
- 20 August 2026
- Published by Springer Nature in VirusDisease
- Vol. 37 (3) , 391-395
Evaluation of the quantiplus rabies virus detection kit for diagnosis of rabies in humans and animals
- 30 December 2025
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (1) , e70095
Neurological Consequences of CMV Infection: Overview of Pathogenesis and Host Responses
Human cytomegalovirus (CMV), a member of the Herpesviridae family, is a ubiquitous pathogen that causes mild or asymptomatic infection in healthy individuals but leads to severe complications in immunocompromised patients and congenitally infected newborns. CMV exhibits marked neurotropism, and infection of the central nervous system (CNS) can result in a broad spectrum of neurological manifestations, including encephalitis, cognitive impairment, and developmental anomalies such as microcephaly, cerebral palsy, and sensorineural hearing loss. Though the clinical importance of CMV on the nervous system is well known and studied, the molecular mechanisms underlying CMV neuropathogenesis remain incompletely understood. In this review we present current knowledge on CMV infection of the CNS, highlighting the viral and host determinants that influence neurotropism, latency, immune evasion, and neural injury. We discuss important molecular pathways involved in viral entry, replication, and host immune modulation that contribute to CNS pathology. The article summarises recent insights from in vitro and in vivo models elucidating how CMV interacts with cells of CNS to disrupt neurodevelopment and brain homoeostasis. Furthermore, we review the neurological manifestations of CMV with emphasis on long term neurological sequelae of congenital and acquired CMV infection, as well as characteristic radiological findings associated with CMV neuroinfection. Understanding the complex interplay between CMV and the host nervous system is essential for identifying therapeutic targets and developing effective preventive strategies. This review aims to provide a comprehensive overview of CMV neuropathogenesis and to identify critical knowledge gaps that can guide future research on CMV‐associated neurological disease.
- 30 December 2025
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (1) , e70095
Neurological Consequences of CMV Infection: Overview of Pathogenesis and Host Responses
Human cytomegalovirus (CMV), a member of the Herpesviridae family, is a ubiquitous pathogen that causes mild or asymptomatic infection in healthy individuals but leads to severe complications in immunocompromised patients and congenitally infected newborns. CMV exhibits marked neurotropism, and infection of the central nervous system (CNS) can result in a broad spectrum of neurological manifestations, including encephalitis, cognitive impairment, and developmental anomalies such as microcephaly, cerebral palsy, and sensorineural hearing loss. Though the clinical importance of CMV on the nervous system is well known and studied, the molecular mechanisms underlying CMV neuropathogenesis remain incompletely understood. In this review we present current knowledge on CMV infection of the CNS, highlighting the viral and host determinants that influence neurotropism, latency, immune evasion, and neural injury. We discuss important molecular pathways involved in viral entry, replication, and host immune modulation that contribute to CNS pathology. The article summarises recent insights from in vitro and in vivo models elucidating how CMV interacts with cells of CNS to disrupt neurodevelopment and brain homoeostasis. Furthermore, we review the neurological manifestations of CMV with emphasis on long term neurological sequelae of congenital and acquired CMV infection, as well as characteristic radiological findings associated with CMV neuroinfection. Understanding the complex interplay between CMV and the host nervous system is essential for identifying therapeutic targets and developing effective preventive strategies. This review aims to provide a comprehensive overview of CMV neuropathogenesis and to identify critical knowledge gaps that can guide future research on CMV‐associated neurological disease.
- 29 December 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (1) , e70785
Epstein‐Barr Virus (EBV) and Autoimmune Diseases: Pathogenic Mechanisms and Therapeutic Insights
Epstein‐Barr virus (EBV), a ubiquitous human γ‐herpesvirus infecting over 90% of the global population, has been increasingly implicated as a key environmental trigger in the development of various autoimmune diseases, including multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA). EBV latent proteins (e.g., EBNA1, EBNA2, LMP1) mimic host antigens and dysregulate B and T cell responses, promoting autoreactivity. Novel therapeutics, including small‐molecule latency disruptors, EBV‐specific T cell therapies, and advanced B‐cell depletion strategies, have shown promise in addressing EBV‐driven autoimmunity. Understanding its pathogenic mechanisms and therapeutic implications is critical for improving disease management. This review summarises EBV's roles in autoimmunity through mechanisms including molecular mimicry, B‐cell transformation, and immune dysregulation. It also examines emerging antiviral and immune‐modulating strategies targeting EBV infection and latency.
- 29 December 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 98 (1) , e70785
Epstein‐Barr Virus (EBV) and Autoimmune Diseases: Pathogenic Mechanisms and Therapeutic Insights
Epstein‐Barr virus (EBV), a ubiquitous human γ‐herpesvirus infecting over 90% of the global population, has been increasingly implicated as a key environmental trigger in the development of various autoimmune diseases, including multiple sclerosis (MS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA). EBV latent proteins (e.g., EBNA1, EBNA2, LMP1) mimic host antigens and dysregulate B and T cell responses, promoting autoreactivity. Novel therapeutics, including small‐molecule latency disruptors, EBV‐specific T cell therapies, and advanced B‐cell depletion strategies, have shown promise in addressing EBV‐driven autoimmunity. Understanding its pathogenic mechanisms and therapeutic implications is critical for improving disease management. This review summarises EBV's roles in autoimmunity through mechanisms including molecular mimicry, B‐cell transformation, and immune dysregulation. It also examines emerging antiviral and immune‐modulating strategies targeting EBV infection and latency.
- 6 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , 139-146
Rabies Despite Postexposure Prophylaxis in High-Burden Settings: Vaccine Failure or Gaps in Healthcare Delivery?
Background: Rabies, a fatal zoonotic encephalitis, is preventable through timely postexposure prophylaxis (PEP), which includes wound care, vaccination, and local infiltration of immunoglobulins. However, reports of rabies despite PEP raise concerns about vaccine efficacy and protocol adherence. This study aimed to assess the burden and underlying causes of such apparent rabies “breakthrough” infections. Methods: This retrospective study analyzed laboratory-confirmed rabies cases from 2018 to 2024 who had received PEP. Cases with at least 1 documented dose of rabies vaccine were included. “True” breakthrough infections (or PEP failures) were defined as rabies occurring despite initiation of PEP within 2 calendar days of exposure and documented completion of all required PEP components. Results: Eighty-nine cases fulfilling the inclusion criteria were analyzed; only 3 were classified as “true” breakthrough infections. A majority of the cases were males (80.90%), and aged less than 15 years (64.04%). Exposure to dogs was reported in 93.26% cases, 80.9% were World Health Organization (WHO) Category III exposures, and 34.83% involved the head or neck. Postexposure prophylaxis was initiated within 2 days in 57.3% of cases; wound care was documented in 56.18%, vaccination completed in 46.07%, and only 26.39% of Category III cases received rabies immunoglobulins without any deviations. Conclusions: The findings indicate that “true” breakthrough infections are uncommon, with most apparent PEP failures resulting from gaps in healthcare delivery. Such failures can undermine public confidence in vaccination, highlighting the need to strengthen awareness among healthcare workers and communities about the critical steps of PEP.
- 6 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , 139-146
Rabies Despite Postexposure Prophylaxis in High-Burden Settings: Vaccine Failure or Gaps in Healthcare Delivery?
Background: Rabies, a fatal zoonotic encephalitis, is preventable through timely postexposure prophylaxis (PEP), which includes wound care, vaccination, and local infiltration of immunoglobulins. However, reports of rabies despite PEP raise concerns about vaccine efficacy and protocol adherence. This study aimed to assess the burden and underlying causes of such apparent rabies “breakthrough” infections. Methods: This retrospective study analyzed laboratory-confirmed rabies cases from 2018 to 2024 who had received PEP. Cases with at least 1 documented dose of rabies vaccine were included. “True” breakthrough infections (or PEP failures) were defined as rabies occurring despite initiation of PEP within 2 calendar days of exposure and documented completion of all required PEP components. Results: Eighty-nine cases fulfilling the inclusion criteria were analyzed; only 3 were classified as “true” breakthrough infections. A majority of the cases were males (80.90%), and aged less than 15 years (64.04%). Exposure to dogs was reported in 93.26% cases, 80.9% were World Health Organization (WHO) Category III exposures, and 34.83% involved the head or neck. Postexposure prophylaxis was initiated within 2 days in 57.3% of cases; wound care was documented in 56.18%, vaccination completed in 46.07%, and only 26.39% of Category III cases received rabies immunoglobulins without any deviations. Conclusions: The findings indicate that “true” breakthrough infections are uncommon, with most apparent PEP failures resulting from gaps in healthcare delivery. Such failures can undermine public confidence in vaccination, highlighting the need to strengthen awareness among healthcare workers and communities about the critical steps of PEP.
- Open Access
- 28 October 2025
- Published by Elsevier in Infectious Diseases Now
- Vol. 55 (8) , 105179
Chandipura virus: A comprehensive review
- 28 October 2025
- Published by Elsevier in Infectious Diseases Now
- Vol. 55 (8) , 105179
Open AccessChandipura virus: A comprehensive review
- 6 February 2025
- Published by Wiley in Microbiology and Immunology
- Vol. 69 (4) , 212-219
Neurofilament Light Chain: A Potential Diagnostic Biomarker for Rabies
Rabies is a fatal, acute progressive encephalomyelitis caused by the rabies virus and other Lyssaviruses. Several other clinical conditions can mimic rabies. Antemortem laboratory diagnosis remains challenging and requires multiple or serial sampling for confirmation. Measurement of host‐based biomarkers is an emerging area of research in infectious diseases; however, a reliable biomarker for rabies remains elusive. In this study, neurofilament light chain (NfL), an established marker of neuronal injury, has been investigated as a potential diagnostic marker for rabies. NfL levels were measured using the Simoa NfL v2 kit in serum and cerebrospinal fluid (CSF) samples received for routine diagnostic testing from encephalitis cases (rabies, n = 31; other encephalitides, n = 30) and controls (n = 24). The median serum NfL level in the rabies group was significantly higher than that in the control group (adjusted p < 0.001), as well as the other encephalitides group (adjusted p = 0.024). Furthermore, the median CSF NfL level in the rabies group was significantly higher than that in the other encephalitides group (p < 0.001). There were no significant differences in serum or CSF NfL levels in rabies cases with different clinical presentations, prior vaccination status, or incubation period. These findings demonstrate for the first time that rabies can be differentiated from other causes of encephalitis by extremely high NfL levels.
- 6 February 2025
- Published by Wiley in Microbiology and Immunology
- Vol. 69 (4) , 212-219
Neurofilament Light Chain: A Potential Diagnostic Biomarker for Rabies
Rabies is a fatal, acute progressive encephalomyelitis caused by the rabies virus and other Lyssaviruses. Several other clinical conditions can mimic rabies. Antemortem laboratory diagnosis remains challenging and requires multiple or serial sampling for confirmation. Measurement of host‐based biomarkers is an emerging area of research in infectious diseases; however, a reliable biomarker for rabies remains elusive. In this study, neurofilament light chain (NfL), an established marker of neuronal injury, has been investigated as a potential diagnostic marker for rabies. NfL levels were measured using the Simoa NfL v2 kit in serum and cerebrospinal fluid (CSF) samples received for routine diagnostic testing from encephalitis cases (rabies, n = 31; other encephalitides, n = 30) and controls (n = 24). The median serum NfL level in the rabies group was significantly higher than that in the control group (adjusted p < 0.001), as well as the other encephalitides group (adjusted p = 0.024). Furthermore, the median CSF NfL level in the rabies group was significantly higher than that in the other encephalitides group (p < 0.001). There were no significant differences in serum or CSF NfL levels in rabies cases with different clinical presentations, prior vaccination status, or incubation period. These findings demonstrate for the first time that rabies can be differentiated from other causes of encephalitis by extremely high NfL levels.
- Open Access
- 14 September 2024
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 30, 100485
Evolving dengue serotype distribution with dominance of dengue virus- 3 in Bangalore: critical insights for vaccine efficacy and implementation
- 14 September 2024
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 30, 100485
Open AccessEvolving dengue serotype distribution with dominance of dengue virus- 3 in Bangalore: critical insights for vaccine efficacy and implementation
- 20 July 2024
- Published by Elsevier in Infectious Diseases Now
- Vol. 54 (6) , 104954
Buffalopox: An emerging zoonotic challenge
- 20 July 2024
- Published by Elsevier in Infectious Diseases Now
- Vol. 54 (6) , 104954
Buffalopox: An emerging zoonotic challenge
- 20 September 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (9) , e29110
Evaluation of a rapid, chip‐based, micro‐PCR assay for detection of rabies virus in human and canine specimens
Rabies, a lethal zoonotic encephalitis, remains a significant global health concern, causing an estimated 60 000 annual fatalities worldwide. Dogs serve as the primary reservoirs and vectors for transmitting this infection to humans. Definitive diagnosis of rabies in both human and animal cases necessitates laboratory testing involving various clinical specimens. However, the complexity of laboratory infrastructure and the need for skilled personnel, along with the challenge of maintaining cold‐chain integrity during sample referral, hinder the decentralization of diagnostic facilities. This study aimed to assess the efficacy of the Truenat rabies assay, a rapid, portable, semiautomated, and closed PCR‐based system, for the diagnosis of rabies in both humans and animals. The Truenat assay demonstrated a sensitivity of 100% and a specificity of 86.96% when compared with the fluorescent antibody test (FAT), as the reference standard, on 147 canine brain samples tested. Notably, the Truenat assay exhibited a sensitivity and specificity of 100% when tested on 48 human brain specimens. Furthermore, an examination of 148 human antemortem samples (cerebrospinal fluid, saliva, and skin biopsy) using both the Truenat assay and a validated real‐time reverse transcriptase PCR assay revealed a κ value of 0.505, indicative of a moderate level of agreement between the two tests. Thus, the Truenat assay offers a robust, reliable, and affordable point‐of‐care solution to enhance rabies diagnostic capacity in endemic areas.
- 20 September 2023
- Published by Wiley in Journal of Medical Virology
- Vol. 95 (9) , e29110
Evaluation of a rapid, chip‐based, micro‐PCR assay for detection of rabies virus in human and canine specimens
Rabies, a lethal zoonotic encephalitis, remains a significant global health concern, causing an estimated 60 000 annual fatalities worldwide. Dogs serve as the primary reservoirs and vectors for transmitting this infection to humans. Definitive diagnosis of rabies in both human and animal cases necessitates laboratory testing involving various clinical specimens. However, the complexity of laboratory infrastructure and the need for skilled personnel, along with the challenge of maintaining cold‐chain integrity during sample referral, hinder the decentralization of diagnostic facilities. This study aimed to assess the efficacy of the Truenat rabies assay, a rapid, portable, semiautomated, and closed PCR‐based system, for the diagnosis of rabies in both humans and animals. The Truenat assay demonstrated a sensitivity of 100% and a specificity of 86.96% when compared with the fluorescent antibody test (FAT), as the reference standard, on 147 canine brain samples tested. Notably, the Truenat assay exhibited a sensitivity and specificity of 100% when tested on 48 human brain specimens. Furthermore, an examination of 148 human antemortem samples (cerebrospinal fluid, saliva, and skin biopsy) using both the Truenat assay and a validated real‐time reverse transcriptase PCR assay revealed a κ value of 0.505, indicative of a moderate level of agreement between the two tests. Thus, the Truenat assay offers a robust, reliable, and affordable point‐of‐care solution to enhance rabies diagnostic capacity in endemic areas.